Last reviewed · How we verify
Melatonin 20 MG
Melatonin 20 MG, marketed by Ilocos Training and Regional Medical Center, holds a position in the sleep aid market with a key composition patent expiring in 2028. The drug's key strength lies in its established market presence and long-term patent protection. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market expansion.
At a glance
| Generic name | Melatonin 20 MG |
|---|---|
| Also known as | MTN, N-acetyl-5-methoxy tryptamine, Melatonin treatment |
| Sponsor | Ilocos Training and Regional Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Melatonin for Post Tonsillectomy Emergence Agitation in Pediatric (NA)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia (EARLY_PHASE1)
- The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional) (PHASE4)
- Melatonin in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (PHASE1, PHASE2)
- Adjuvant Melatonin for Uveal Melanoma (PHASE3)
- Effect of Oral Melatonin Versus Intraoperative Lidocaine Infusion on Incidence of Postoperative Delirium in Elderly Patients Undergoing Total Hip Arthroplasty (NA)
- The Use of Melatonin for Delirium Prevention in Medically Hospitalized Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Melatonin 20 MG CI brief — competitive landscape report
- Melatonin 20 MG updates RSS · CI watch RSS
- Ilocos Training and Regional Medical Center portfolio CI